Phoenix Financial’s Oramed Pharmaceuticals ORMP Stock Holding History

Phoenix Financial’s Portfolio ORMP Stock Details ORMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-10,542	Closed	-$125K	–	327
2022 Q4	$125K	Sell	10,542 -3,092	-23%	-$24K	﹤0.01%	266
2022 Q3	$89K	Sell	13,634 -37,316	-73%	-$302K	﹤0.01%	322
2022 Q2	$231K	Buy	50,950 +22,795	+81%	+$122K	﹤0.01%	346
2022 Q1	$244K	Sell	28,155 -3,173	-10%	-$32.5K	﹤0.01%	357
2021 Q4	$439K	Buy	31,328 +2,722	+10%	+$56.9K	0.01%	298
2021 Q3	$633K	Buy	28,606 +987	+4%	+$16.8K	0.01%	298
2021 Q2	$370K	Buy	+27,619	New	+$316K	0.01%	280
2020 Q4	–	Sell	-197,763	Closed	-$483K	–	411
2020 Q3	$483K	Buy	197,763 +15,503	+9%	+$54K	0.02%	231
2020 Q2	$610K	Buy	+182,260	New	+$612K	0.03%	232

Other funds holding ORMP

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

SIGI

Susquehanna International Group (Ireland) Dublin, Ireland $472M AUM 25.62% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Phoenix Financial's ORMP Position: Q1 2023 in Review

Phoenix Financial sold out of Oramed Pharmaceuticals (ORMP) in Q1 2023, closing a stake of 10,542 shares — an estimated $125K sold.

Phoenix Financial first reported a position in ORMP in Q2 2020 and held it in 9 quarters. The position peaked at $633K in Q3 2021. 61 funds tracked by Wall St. Rank hold ORMP as of Q1 2023.

Phoenix Financial reported no remaining Oramed Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Phoenix Financial sold 10,542 Oramed Pharmaceuticals shares in Q1 2023, an estimated $125K.
Phoenix Financial first reported a position in Oramed Pharmaceuticals in Q2 2020 and held it in 9 quarters.
Phoenix Financial's Oramed Pharmaceuticals position peaked at $633K in Q3 2021.
61 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q1 2023.

Based on Phoenix Financial's 13F filing for Q1 2023, filed 11 May 2023.